Patients with heart failure will be randomized 1:1 to either oral torsemide or oral furosemide prior to hospital discharge. The primary endpoint will be all-cause mortality over the follow-up period. Secondary endpoints are hospitalizations, quality of life, and depression.
TRANSFORM-HF (ToRsemide compArisoN with furoSemide FOR Management of Heart Failure) Study
Investigator: Ambrosy, Andrew
Funder: National Heart, Lung, and Blood Institute